BRIEF published on 07/30/2026 at 23:45, 1 month 13 days ago DBV Technologies Raises $50 Million via ATM Program Nasdaq ADSs DBV Technologies ATM Program RA Capital
PRESS RELEASE published on 07/30/2026 at 23:40, 1 month 13 days ago DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq DBV Technologies announces sale of $50 million of ADSs through its Nasdaq ATM Program to RA Capital Management, L.P. Each ADS represents 5 Ordinary Shares Nasdaq Ads DBV Technologies ATM Program RA Capital
BRIEF published on 07/21/2026 at 11:48, 1 month 23 days ago JP Morgan Chase & Co. reduces its stake in DBV Technologies Share Capital Threshold Crossing DBV Technologies JP Morgan Statement Of Intent
BRIEF published on 07/17/2026 at 23:05, 1 month 26 days ago DBV Technologies launches an ATM financing program SEC Filing DBV Technologies Viaskin® Peanut ATM Program Biopharmaceutical Financing
BRIEF published on 07/17/2026 at 23:05, 1 month 26 days ago DBV Technologies Initiates $150 Million At-The-Market Offering SEC Filing DBV Technologies Viaskin Peanut ATM Program ADS Sales
PRESS RELEASE published on 07/17/2026 at 23:00, 1 month 26 days ago DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales DBV Technologies files $150 million ATM prospectus with SEC for ADSs. Net proceeds to fund manufacturing expansion and product development. Forward-looking statements included Forward-looking Statements Net Proceeds SEC Filing DBV Technologies ATM Prospectus
BRIEF published on 07/16/2026 at 22:15, 1 month 27 days ago DBV Technologies Files 2026 Half-Year Report with AMF Half-year Report AMF Filing DBV Technologies Food Allergies VIASKIN Patch
BRIEF published on 07/16/2026 at 22:15, 1 month 27 days ago DBV Technologies publishes its 2026 Half-Year Financial Report Financial Report Stock Market Listing DBV Technologies Food Allergies Viaskin Technology
PRESS RELEASE published on 07/16/2026 at 22:10, 1 month 27 days ago DBV Technologies Announces the Filing of its 2026 Half-Year Report ? Conditions for Accessing or Consulting the Report DBV Technologies files 2026 Half-Year Report with French market authority AMF. Company develops treatments for food allergies with VIASKIN patch technology Half-year Report DBV Technologies Food Allergies French Market Authority VIASKIN Patch Technology
BRIEF published on 07/16/2026 at 22:06, 1 month 27 days ago DBV Technologies Releases 2026 Mid-Year Financial Update and Progress Report Financial Results Cash Position Clinical Trials FDA Submission VIASKIN® Peanut Patch
Published on 09/12/2026 at 02:35, 1 day 14 hours ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 1 day 18 hours ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 21:25, 1 day 20 hours ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 2 days ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 17:50, 23 hours 34 minutes ago New Delhi Marks UN Day for South-South Cooperation with Push to Scale Dryland Innovation Across the Global South
Published on 09/12/2026 at 07:30, 1 day 9 hours ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 1 day 19 hours ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 1 day 19 hours ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 1 day 21 hours ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 07:00, 2 days 10 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/10/2026 at 19:30, 2 days 21 hours ago Availability of the 2026 Interim Financial Report
